Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Depreciation & Amortization (CF) (2022 - 2025)

Coeptis Therapeutics Holdings has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $295303.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $295303.0 for Q4 2025, up 18.02% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (up 18.02% YoY), and the annual figure for FY2025 was $1.2 million, up 18.02%.
  • Depreciation & Amortization (CF) for Q4 2025 was $295303.0 at Coeptis Therapeutics Holdings, roughly flat from $295303.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for COEPW hit a ceiling of $295303.0 in Q1 2025 and a floor of $250211.0 in Q1 2024.
  • Median Depreciation & Amortization (CF) over the past 4 years was $250328.0 (2022), compared with a mean of $261542.4.
  • Biggest five-year swings in Depreciation & Amortization (CF): dropped 0.04% in 2024 and later rose 18.02% in 2025.
  • Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) stood at $250346.0 in 2022, then dropped by 0.01% to $250310.0 in 2023, then fell by 0.04% to $250212.0 in 2024, then rose by 18.02% to $295303.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $295303.0 (Q4 2025), $295303.0 (Q3 2025), and $295303.0 (Q2 2025) per Business Quant data.